Endo Completes International Pharmaceuticals Business Divestiture

Rhea-AI Summary

Endo (NDOI) has completed the divestiture of its International Pharmaceuticals business, primarily operated through Paladin Pharma Inc., to Knight Therapeutics Inc. The total transaction value is up to $105 million, structured as $79 million paid at closing, $11 million in permitted holdbacks, and potential milestone payments of up to $15 million. The sale represents a significant strategic move for Endo, affecting its international market presence and financial position.

Positive

• Immediate cash injection of $79 million strengthening company's balance sheet
• Potential for additional $26 million through holdbacks and milestone payments
• Strategic streamlining of operations by divesting international business

Negative

• Loss of revenue stream from international pharmaceuticals business
• Reduced global market presence and geographical diversification
• $15 million of total consideration is contingent on uncertain milestone achievements

MALVERN, Pa., June 17, 2025 /PRNewswire/ -- Endo, Inc. ("Endo" or the "Company") (OTCQX: NDOI) today announced that it has completed the previously announced divestiture of its International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc., to Knight Therapeutics Inc.

Total cash consideration for the sale is up to approximately $105 million, consisting of approximately $79 million paid at closing, approximately $11 million related to certain permitted holdbacks, and up to $15 million in future payments contingent upon the achievement of certain milestones.

About Endo

Endo is a diversified pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements including, but not limited, to any statements relating to the divestiture of the International Pharmaceuticals business and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: the costs and post-closing obligations related to the divestiture and the potential impact of the divestiture on Endo's businesses; changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-K and Form 10-Q.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-completes-international-pharmaceuticals-business-divestiture-302483838.html

SOURCE Endo, Inc.

FAQ

How much did Knight Therapeutics pay for Endo's International Pharmaceuticals business?

Knight Therapeutics paid $79 million at closing, with additional potential payments of up to $26 million through holdbacks and milestone achievements, for a total possible consideration of $105 million.

What assets were included in Endo's (NDOI) divestiture to Knight Therapeutics?

The divestiture included Endo's International Pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma Inc.

What is the structure of the payment for Endo's International Pharmaceuticals sale?

The payment structure includes $79 million paid at closing, $11 million in permitted holdbacks, and up to $15 million in milestone-based future payments.

When did Endo complete the sale of its International Pharmaceuticals business?

Endo completed the sale of its International Pharmaceuticals business on June 17, 2025.

What is the potential total value of Endo's International Pharmaceuticals business sale?

The total potential value of the sale is approximately $105 million, subject to certain conditions and milestone achievements.